Ipswich Investment Management Co. Inc. Purchases 82 Shares of Danaher Co. (NYSE:DHR)

Ipswich Investment Management Co. Inc. lifted its position in Danaher Co. (NYSE:DHR) by 1.4% in the 3rd quarter, HoldingsChannel.com reports. The fund owned 6,008 shares of the conglomerate’s stock after acquiring an additional 82 shares during the quarter. Ipswich Investment Management Co. Inc.’s holdings in Danaher were worth $1,670,000 as of its most recent SEC filing.

Other hedge funds and other institutional investors have also bought and sold shares of the company. nVerses Capital LLC bought a new stake in shares of Danaher during the 2nd quarter worth $25,000. CarsonAllaria Wealth Management Ltd. bought a new stake in Danaher in the second quarter worth about $25,000. MFA Wealth Advisors LLC purchased a new position in Danaher in the second quarter valued at about $51,000. Financial Connections Group Inc. bought a new position in shares of Danaher during the 2nd quarter valued at approximately $51,000. Finally, Western Pacific Wealth Management LP purchased a new stake in shares of Danaher during the 1st quarter worth approximately $55,000. Hedge funds and other institutional investors own 79.05% of the company’s stock.

Danaher Stock Performance

NYSE:DHR opened at $230.51 on Friday. Danaher Co. has a twelve month low of $206.30 and a twelve month high of $281.70. The company has a quick ratio of 1.01, a current ratio of 1.37 and a debt-to-equity ratio of 0.32. The stock has a market cap of $166.49 billion, a P/E ratio of 43.99, a PEG ratio of 4.44 and a beta of 0.85. The business’s 50-day moving average price is $262.20 and its two-hundred day moving average price is $260.38.

Danaher (NYSE:DHR) last announced its earnings results on Tuesday, October 22nd. The conglomerate reported $1.71 earnings per share (EPS) for the quarter, beating the consensus estimate of $1.57 by $0.14. The business had revenue of $5.80 billion during the quarter, compared to analyst estimates of $5.59 billion. Danaher had a net margin of 16.39% and a return on equity of 10.62%. Danaher’s revenue for the quarter was up 3.1% on a year-over-year basis. During the same period in the previous year, the business posted $2.02 earnings per share. As a group, equities analysts predict that Danaher Co. will post 7.51 EPS for the current fiscal year.

Danaher Dividend Announcement

The company also recently announced a quarterly dividend, which was paid on Friday, October 25th. Investors of record on Friday, September 27th were paid a $0.27 dividend. The ex-dividend date of this dividend was Friday, September 27th. This represents a $1.08 dividend on an annualized basis and a yield of 0.47%. Danaher’s dividend payout ratio is presently 20.61%.

Insiders Place Their Bets

In other Danaher news, SVP Georgeann Couchara sold 952 shares of Danaher stock in a transaction that occurred on Monday, August 26th. The shares were sold at an average price of $268.37, for a total transaction of $255,488.24. Following the transaction, the senior vice president now directly owns 4,212 shares of the company’s stock, valued at approximately $1,130,374.44. This trade represents a 18.44 % decrease in their ownership of the stock. The transaction was disclosed in a legal filing with the SEC, which can be accessed through this hyperlink. Corporate insiders own 11.10% of the company’s stock.

Analyst Upgrades and Downgrades

DHR has been the topic of several research analyst reports. Barclays dropped their price objective on Danaher from $285.00 to $275.00 and set an “equal weight” rating on the stock in a research note on Wednesday, October 23rd. The Goldman Sachs Group upped their price target on Danaher from $225.00 to $250.00 and gave the company a “neutral” rating in a research report on Wednesday, July 24th. Evercore ISI lifted their price objective on Danaher from $275.00 to $278.00 and gave the stock an “outperform” rating in a report on Tuesday, October 1st. Royal Bank of Canada dropped their price objective on shares of Danaher from $333.00 to $311.00 and set an “outperform” rating on the stock in a report on Wednesday, October 23rd. Finally, UBS Group reduced their target price on shares of Danaher from $309.00 to $305.00 and set a “buy” rating for the company in a research note on Wednesday, October 23rd. Five analysts have rated the stock with a hold rating and fifteen have assigned a buy rating to the company’s stock. According to MarketBeat.com, the stock currently has an average rating of “Moderate Buy” and an average price target of $287.16.

About Danaher

Danaher Corporation designs, manufactures, and markets professional, medical, industrial, and commercial products and services worldwide. The Biotechnology segments offers bioprocess technologies, consumables, and services that advance, accelerate, and integrate the development and manufacture of therapeutics; cell line and cell culture media development services; cell culture media, process liquids and buffers for manufacturing, chromatography resins, filtration technologies, aseptic fill finish; single-use hardware and consumables and services, such as the design and installation of full manufacturing suites; lab filtration, separation, and purification; lab-scale protein purification and analytical tools; reagents, membranes, and services; and healthcare filtration solutions.